Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America.

The proportion of HPV16 and 18-associated cervical cancer (CC) appears rather constant worldwide (≥70%), but the relative importance of the other HR-HPV differs slightly by geographical region. Here, we studied the HPV genotype distribution of HPV positive Latin American (LA) women by histological grade, in a sub-cohort from the ESTAMPA study; we also explored the association of age-specific HPV genotypes in severe lesions. Cervical samples from 1,252 participants (854 ≤CIN1, 121 CIN2, 194 CIN3 and 83 CC) were genotyped by two PCRs-Reverse Blotting Hybridization strategies: i) Broad-Spectrum General Primers 5+/6+ and ii) PGMY9/11 PCRs. HPV16 was the most frequently found genotype in all histological grades, and increased with the severity of lesions from 14.5% in ≤ CIN1, 19.8% in CIN2, 51.5% in CIN3 to 65.1% in CC (p < 0.001). For the remaining HR-HPVs their frequency in CC did not increase when compared to less severe categories. The nonavalent vaccine HR-types ranked at the top in CC, the dominant ones being HPV16 and HPV45. HR-HPV single infection occurs, respectively, in 57.1% and 57.0% of ≤CIN1 and CIN2, increasing to 72.2% and 91.6% in CIN3 and CC (p<0.001). No association between age and HPV type was observed in CC, although the risk of HPV16 infection in CIN3 cases increased with age. Results confirm the relevance of HPV16 in the whole clinical spectrum, with a strong rise of its proportion in CIN3 and cancer. This information will be relevant in evaluating the impact of HPV vaccination, as a baseline against which to compare genotype changes in HPV type-specific distribution as vaccinated women participate in screening in LA region. Likewise, these data may help select the best HPV testing system for HPV-based efficient, affordable, and sustainable screening programmes.

Reduction in Vaccine HPV Type Infections in a Young Women Group (18-25 Years) Five Years after HPV Vaccine Introduction in Colombia.

In Colombia, the human papillomavirus (HPV) vaccine was launched in 2012 in the context of a school-based national vaccination program targeting girls ages 9 to 14 and offering catch-up vaccination for girls ages 14 to 17. In this study, we evaluated the program's impact on type-specific HPV infection by comparing HPV cervical prevalence among vaccinated and nonvaccinated women. This is a comparative cross-sectional study conducted 5 years after the quadrivalent HPV vaccination implementation in a sentinel Colombian City. This study included young women (18-25 years old) who had been vaccinated in the catch-up group and were attending universities and technical institutions, and women who attended primary health care facilities for Pap smear screening. The HPV prevalence of 1,287 unvaccinated women was compared with the prevalence of 1,986 vaccinated women. The prevalence of HPV16/18 infections was significantly lower in vaccinated compared with unvaccinated women (6.5% vs. 15.4%; P < 0.001), whereas for HPV6/11 infections, a decrease of 63.7% in vaccinated women (1.02% vs. 2.81%) was observed. The adjusted effectiveness to HPV16/18 was 61.4%; 95% CI, 54.3%-67.6%. However, the effectiveness against HPV16/18 was significantly higher among women vaccinated before their sexual debut 91.5%; 95% CI, 86.8-94.5, compared with effectiveness for vaccination after their sexual debut, 36.2%; 95% CI, 23.6-46.7. Five years after the introduction of HPV vaccines in Colombia, high effectiveness of HPV to prevent HPV16/18 infections is observed in the catch-up cohorts including virgin and sexually active women. PREVENTION RELEVANCE: Monitoring HPV vaccines post-licensure plays an important role in assessing the progress of immunization programs, demonstrating the impact of vaccines on the population, and providing data for policy needs. In Colombia, HPV vaccines showed effectiveness when administered before start of sexual activity, and two doses are sufficient to achieve good protection.

Estimation of the Need for Radiation Therapy Services According to the Incidence of Cancer in Colombia to 2035.

PURPOSE: To estimate the supply and demand of current and future radiation therapy services by 2035 for Colombia. METHODS AND MATERIALS: The present study was performed by surveying different radiation therapy services identified in Colombia through the Colombian Association of Radiation Oncology. The demand was estimated based on incident cases and published information on the use of radiation therapy by type of cancer. Future demand was estimated under the assumption that incidence rates do not change and therefore the change in the number of cases is due to the change in the age structure of the Colombian population. Sensitivity analyses were conducted on the percentage of radiation therapy use by type of cancer. A Monte Carlo simulation was carried out to estimate the distribution of cases requiring radiation therapy, the amount of equipment, and the number of staff needed for care with the use of this technology. RESULTS: In total, Colombia has 69 linear accelerators, 2 radiosurgery equipment, 30 high-dose-rate brachytherapy pieces of equipment, 124 radiation therapy oncologists (113 working, 9 not working, and 2 not informed), and 275 radiation therapy technologists as of June 2020. It was estimated that to meet the current cancer burden the country would need a total of 162 radiation therapy oncologists, 121 medical physicists, and 323 radiation therapy technologists and to increase the number of radiation therapy technologists, radiation therapy oncologists, and medical physicists to 491, 246, and 184, respectively, to meet the disease burden by 2035 (73,684-88,743 cases per year). CONCLUSIONS: In Colombia it is estimated that there is a deficit of human resources and technology for radiation therapy; therefore, there is need to investment resources from the public and private sectors to provide timely and quality care to cancer patients requiring this treatment.

Accuracy of combined molecular and morphology-based triage for HPV-positive women in routine cervical cancer screening services from Colombia.

WHO cervical cancer elimination goals comprise 70% of highly-sensitive screening coverage and 90% treatment of precancerous lesions. Triage for HPV-positive women may challenge sensitivity of screening algorithms and women's follow-up, particularly in low- and middle-income countries (LMIC) where screening quality and protocol adherence are frequently deficient. We aimed to determine the accuracy of triage for HPV positive women in routine screening services from Colombia by a prospective cross-sectional study. Consecutively, HPV DNA-positive women underwent six triage strategies (conventional cytology, two methods of visual inspection, HPV16/18/45-genotyping, telomerase, and HPV mRNA). Positive triage results underwent regular colposcopy/biopsy in public hospitals. Adjusted sensitivity, specificity, and predictive values for CIN2+/CIN3+ were estimated for stand-alone and combined tests. We explored the impact of triage strategies on referral rates and the complete screening algorithm (screening plus triage). Overall 16,242 women underwent HPV screening and 1789 (11.0%) were HPV-positive. In total, 20.1% of women were lost to follow-up. mRNA showed the highest positivity rate (0.64 among HPV-positive and 0.05 among the total screened cohort), the highest sensitivity (0.94 95%CI 0.75-0.96), and the lowest specificity (0.36 95%CI 0.29-0.43). Parallel testing with HPV-mRNA revealed the highest increase in sensitivity for all triage strategies. Accuracy of cytology and visual inspection differ between screening units but parallel testing with HPV16/18/45 genotyping significantly increased their sensitivity (over 0.80). Morphology-based triage for HPV-positive women remains a suitable alternative for routine practice in LMIC if combined with HPV16/18/45-genotyping; however, point-of-care triage would be preferable to reduce losses to follow-up. HPV-mRNA triage deserves cost-benefit analyses.

Breast cancer in Colombia: a growing challenge for the healthcare system.

AIM: To provide a comprehensive overview of breast cancer in Colombia. METHODS: Data on breast cancer in Colombia are scarce. We present incidence data from population-based cancer registries that represent 4 distinct regions of the country. Other data originate from non-governmental institutions and healthcare providers within Colombia, official sources, expert opinion, Colombian legislation, and the Cancer Mortality Atlas publishes by Colombian National Cancer Institute. RESULTS: In Colombia, the age-standardized incidence rate remained relatively stable between 2012 and 2020 (43.1 to 47.8 cases per 100,000 women-years); Additionally, survival since 1995 has presented a substantial improvement from 65.7 to 72.1. In 33% of cases, the diagnosis of breast cancer was made in advanced stages, stage III or higher. The health demography survey conducted in 2015 showed that the participation in mammography screening in women aged 40 to 69 remains low 48.1%. Some limitations regarding access to early detection and diagnosis include economic strata, health insurance coverage, origin, and accessibility. On average, a 90-day period was reported from onset of symptoms to diagnosis of breast cancer. CONCLUSION: The first action towards improving outcomes in breast cancer should be to improve stage at diagnosis and timely access to care.

Reporte de caso: Presentación clínica e importancia de coinfecciones durante pandemia por COVID-19 en pacientes con neoplasias malignas / Case report: Clinical presentation and importance of coinfections during the COVID-19 pandemic in patients with malignant neoplasms

Resumen El nuevo coronavirus (ahora llamado SARS-CoV2) descubierto en China, se convirtió en pandemia en menos de tres meses. Pacientes infectados por SARS-CoV-2 presentan síntomas de fiebre, disnea, linfopenia, anosmia, disgeusia y cambios radiográficos pulmonares en vidrio esmerilado. La presentación clínica oscila en enfermedad leve a falla respiratoria, choque y disfunción multiorgánica. Se informan los dos primeros casos de pacientes con cáncer y diagnóstico de Covid19 con coinfección en el Instituto Nacional de Cancerología, ESE.

Abstract The new coronavirus (now called SARS-CoV2) discovered in China became a pandemic in less than three months. Patients infected with SARS-CoV-2 present symptoms of fever, dyspnea, lymphopenia, anosmia, dysgeusia, and ground-glass opacity in chest computed tomography. The clinical presentation ranges from mild disease to respiratory failure, shock, and multi-organ failure. The first two cases of patients with cancer and diagnosis of Covid-19 with co-infections are reported at Instituto Nacional de Cancerología, ESE.

Políticas basadas en la evidencia científica: El caso del control del cáncer de mama en Colombia / Evidence-based policies: The case of breast cancer control in Colombia

Resumen Colombia tiene un riesgo intermedio a desarrollar cáncer de mama con una tasa de incidencia estandarizada por edad en de 44,1 por 100.000 mujeres. A pesar de que en el país se recomienda la tamización mediante mamografía, en mujeres de 50 a 69 años y examen clínico de mama anual, así como detección temprana para mujeres sintomáticas independientemente de la edad; en Colombia no se ha podido reducir la mortalidad por esta causa. Múltiples causas parecen explicar este problema: baja participación en las actividades de tamización con mamografía por parte de la población objeto; baja calidad de la mamografía, y barreras de acceso para el diagnóstico oportuno y el tratamiento integral. Frente a esta problemática el 3 de octubre fue aprobado en primer debate el proyecto de ley 259 de 2019 Cámara Proyecto de Ley "Por medio de la cual se establecen medidas para la prevención, diagnóstico, tratamiento oportuno, rehabilitación, y cuidados paliativos del cáncer de mama y se dictan otras disposiciones". A fin de revisar el soporte científico del contenido del proyecto de ley y aportar a su adecuada discusión, el Instituto Nacional de Cancerologia (INC) realizó un foro el 9 de diciembre de 2019. El propósito de este artículo es presentar el análisis de los puntos de mayor controversia desde una perspectiva científica, como base para la adecuada toma de decisiones en materia de políticas de salud pública.

Abstract Colombia ranks at an intermediate risk level regarding the development of breast cancer, with an age-standardized incidence rate of 44.1 per 100,000 women. Although mammography screening and annual Clinical Breast Examination for women aged 50 to 69 are recommended in Colombia, as well as early detection for symptomatic women regardless of age, mortality from this cause has not been reduced in Colombia. Multiple causes seem to explain this problem: low participation of the target population in mammography screening activities, poor quality of mammography, and access barriers for timely diagnosis and comprehensive treatment. In view of this problem, the House of Representatives approved in first debate last October 3 Bill No. 259 of 2019 "by means of which measures and other provisions for prevention, diagnosis, timely treatment, rehabilitation, and palliative care of breast cancer are set up". The Colombian National Cancer Institute INC, held a forum on December 9, 2019, aimed at reviewing the scientific support of the content of the bill and contribute to its proper discussion. The purpose of this paper is to present the analysis of the most controversial points from a scientific perspective, as a basis for appropriate decision-making in public health policy.

Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report.

The Human Papillomavirus (HPV) Prevention and Control Board is an independent multidisciplinary board of international experts that disseminates relevant information on HPV to a broad array of stakeholders and provides guidance on strategic, technical and policy issues in the implementation of HPV control programs. In response to drastic drop of vaccine coverage following the adverse event crisis in Carmen del Bolivar, Colombia, the HPV Prevention and Control Board in collaboration with the Colombian National Cancer Institute and Colombian League Against Cancer convened a meeting in Bogota, Columbia (November 2018). The goal of the meeting was to bring together national and international group of experts to report the disease burden, epidemiology and surveillance of HPV and HPV-related cancers, to discuss the successes and especially the challenges of HPV vaccination and screening in Colombia, as well as the lessons learnt from neighbouring countries. The meeting provided a platform to confer various stakeholder's perspectives, including the role of the Colombian healthcare system and to catalyse various parts of the public health community in Colombia into effective action. The conclusion of the meeting included following suggestions to strengthen HPV prevention and control: 1) Re-introducing school-based vaccine programs, 2) Integrating primary and secondary prevention programs, 3) Developing an innovative crisis communication plan targeting healthcare workers, teachers and general population, 4) Building trust through efficient and timely communication, 5) Building strong relationship with media to ensure a stable vaccination campaign support, and 6) Promoting empathy among healthcare professionals towards patients to build trust and communicate effectively.

Psycho-social impact of positive human papillomavirus testing in Jujuy, Argentina results from the Psycho-Estampa study.

Human papillomavirus (HPV) testing can have a negative impact on women's lives which might also result in abandoning the follow-up and treatment process. This study measured the psycho-social impact of HPV-positivity among HPV-tested women from Jujuy, Argentina, a middle-low income setting. In this cross-sectional study (2015-2016), the psycho-social impact of HPV-positivity was measured using the Psycho-Estampa Scale, specifically designed and validated to be used in screening contexts. We measured mean scores for each of the five scale domains, and the Overall Impact score (Values from 1: No impact to 4: Heavy impact). We compared scores according to cytology triage diagnosis using ordinal logistic regression. A total of 163 HPV-positive women were recruited at the Centro Carlos Alvarado hospital and included in the study sample; of these, 124 (76.1%) had normal triage cytologies. The overall Impact score was between low and moderate (mean:2.56, SD:0.65). The highest psycho-social impact was measured in the Worries about cancer and treatment domain (mean score:3.60, SD:0.60), followed by Sexuality domain (mean:2.50; SD:1.00). The Uncertainty about information provided by health providers domain had the lowest mean score (mean:2.14, SD:0.73). Compared to women with normal cytologies (n = 124), women with abnormal cytologies (n = 39) had a higher likelihood of greater overall Psycho-social Impact (OR: 2.91; p = 0.0036). No statistically significant differences were found in scores of specific domains according to cytology results. It is important to devise specific counseling interventions to reduce the psycho-social impact of HPV-Testing as primary screening and its potential effect on completion of the diagnosis/ treatment process.

Importancia del acceso de los registros de cáncer de base poblacional a las estadísticas vitales: barreras identificadas en Colombia / Importance of access of population-based cancer registries to vital statistics: barriers identified in Colombia

Resumen Los registros de cáncer de base poblacional (RCBP) son los responsables del reporte de incidencia, mortalidad y supervivencia de los pacientes con cáncer para sus respectivas poblaciones. Los RCBP del país son definidos por la legislación colombiana como fuentes de información de los registros nacionales de cáncer para adultos y niños, pero carecen de un soporte jurídico que permita el acceso a las fuentes oficiales de información nacional y enfrentan restricciones dadas por la ley para el tratamiento de datos personales que impide la transferencia de información de los registros nacionales de cáncer y todas sus fuentes hacia los RCBP. Se analizarán los problemas de acceso a la información de estadísticas vitales del país, así como las consecuencias de estas barreras de acceso para los RCBP, y se presentarán argumentos que sustenten la necesidad de que los RCBP puedan acceder a la información necesaria para poder cumplir su objetivo.

Abstract Population-based cancer registries (PBCR) are responsible for reporting incidence, mortality and survival for cancer patients in their respective populations. Colombian legislation assigned the PBCR as sources of information for the national observatory on cancer. However, the PBCR lack legal support that officially assures access to official sources of national vital statistics and information on healthcare consumption; they face restrictions provided by law for the processing of personal data that prevents the transfer of information from national cancer databases and all their sources to the PBCR. We provide analysis of the problems of access to information on vital statistics of the country and the consequences of these access barriers for the PBCR, the presented arguments illustrate the need for the PBCR to have a smooth access to such information to be able to comply with their objectives.

Educación en Colombia para la detección temprana del cáncer de mama / Education for the early detection of breast cancer in Colombia

Introducción. El cáncer de mama representa un problema de salud pública cada vez mayor en Colombia. La mayoría de los estudiantes de medicina y de los profesionales de la salud no reciben capacitación para la detección temprana del cáncer de mama. Objetivo. Describir el proceso llevado a cabo por el Instituto Nacional de Cancerología de Colombia, para capacitar a los profesionales de la salud (médicos generales, ginecólogos, médicos familiares y enfermeras) en la detección temprana del cáncer de mama, mediante cursos presenciales y virtuales. Resultados. Con las dos modalidades de cursos, 1.875 profesionales de la salud han sido capacitados, la mayoría de ellos mediante el curso virtual (n=1.294; 73,0 %). Asimismo, los médicos generales han sido los profesionales que más se han certificado mediante alguna de las dos modalidades del curso (n=919; 49,0 %). Los dos cursos generan gran satisfacción en los participantes, con una tasa de certificación del 100 % en la modalidad presencial y del 73,0 % en la virtual. Conclusiones. Es difícil medir el impacto de la capacitación profesional en el diagnóstico precoz del cáncer de mama, porque la mayoría de las regiones de Colombia no tienen registros de cáncer. Es probable que, con un tiempo mayor de seguimiento, se logre medir el impacto real de los cursos en la detección temprana del cáncer de mama y, por ende, en la mortalidad debida a la enfermedad (AU)

Introduction: Breast cancer represents an increasing public health issue in Colombia. Most undergraduate medical students and health professionals do not receive training in early detection of breast cancer. Material and methods: This article describes the process and achievements developed by the National Cancer Institute of Colombia (NCIC) to train health professionals (general practitioners [GP], gynecologists, family doctors and chief nurses) in early detection of breast cancer through two modalities courses: physical presence and virtual. Results: With these two course modalities 1,875 health professionals have been trained, most of them were certified through the virtual course (n=1.294; 73,.0 %). Most of the trained health professionals were GP (n=919; 49,0 %). Both modalities had a high level of satisfaction of the participants, a certification rate of 100 % in the face-to-face modality and 73.0 % in the virtual one. Conclusions: It is difficult to measure the impact of professional training in the clinical staging of breast cancer mainly because most regions in Colombia do not have cancer records. We should have a longer follow-up time to be able to measure the real impact in achieving lower clinical staging and, therefore, to reduce mortality due to the disease (AU)

Oncology services supply in Colombia.

OBJECTIVE: To characterize the current status of oncological services supply in Colombia. METHODS: A descriptive analysis of oncological services for cancer care in the adult and infant population that meet the requirements for operation according to the Special Register of Health Service Providers was carried out. The case - by - provider ratio was calculated based on the cancer incidence estimated for Colombia by the National Cancer Institute. RESULTS: Were identified 1,780 qualified oncology health services in the country related to specialties for providing care to cancer patients. Twenty five providers nationwide had all three qualified services: chemotherapy, radiotherapy and surgery. Nearly 50% of the offer was concentrated in Bogotá, Antioquia and Valle del Cauca. Putumayo and the Amazonas group departments, with the exception of Vaupés, did not show any oncological services. Healthcare Providers were responsible for 87.8%, and independent professionals provided 12.2%. Outpatient services were 66.7% of oncology services, 17.4% was diagnostic support services and therapeutic complementation, and 15.9% was surgical services. 87.9% of the oncological service offer in Colombia takes place in the private sector. CONCLUSIONS: The ratio between the service groups is asymmetric, with few providers jointly offering the basic services for oncology treatment, which reflects how provision is fragmented. It is necessary to redefine the concept of oncology service under a comprehensive care approach and the importance of enabling functional units, comprehensive treatment centers and other forms of care.

OBJETIVO: Caracterizar la situación actual de la oferta de servicios oncológicos en Colombia. MÉTODOS: Se realizó un análisis descriptivo de los servicios oncológicos para la atención de cáncer en población adulta e infantil, que cumplieron con los requisitos para su funcionamiento de acuerdo al Registro Especial de Prestadores de Servicios de Salud. La razón de casos por prestador se calculó a partir de la incidencia de cáncer estimada para Colombia por el Instituto Nacional de Cancerología. RESULTADOS: Se identificaron 1,780 servicios de salud oncológicos habilitados en el país relacionados con especialidades para la atención de pacientes con cáncer. 25 prestadores a nivel nacional contaron con los tres servicios habilitados: quimioterapia, radioterapia y cirugía. Cerca del 50% de la oferta se concentró en Bogotá, Antioquia y Valle del Cauca. Los departamentos de Putumayo y del grupo Amazonas, con excepción de Vaupés, no registraron servicios oncológicos. El 87.8% fue ofertado por Instituciones Prestadoras de Salud y el 12.2% fue provisto por profesionales independientes. El 66.7% de los servicios oncológicos eran de consulta externa, el 17.4% eran servicios de apoyo diagnóstico y complementación terapéutica y el 15.9% servicios quirúrgicos. El 87.9% de la oferta de servicios oncológicos en Colombia está en el sector privado. CONCLUSIONES: La relación entre los grupos de servicios es asimétrica, con pocos prestadores que ofertan de forma conjunta los servicios bases del tratamiento oncológico, lo cual refleja la fragmentación en la prestación. Es necesario redefinir el concepto de servicio oncológico bajo el enfoque de atención integral y la importancia de habilitar unidades funcionales, centros integrales de tratamiento y otras formas de atención.

Pediatric oncology services in Colombia.

In low-income countries, a child diagnosed with cancer has an 80% chance of dying, while in high-income countries more than 80% survive the disease. In Colombia, a middle-income country, the government issued new legislation that promotes the generation of comprehensive care units; nevertheless, seven years after its expedition, no institution has been recognized as such by the Ministry of Health. The objective of this study was to characterize the current offer of oncological services for cancer care in children and to identify the institutions that can be constituted in Units of Comprehensive Care of Childhood Cancer in Colombia. METHODS: descriptive study of secondary source, the Special Register of Health Providers of the Ministry of Health and Social Protection was consulted, in order to identify the institutions that had enabled hospitalization services of medium or high complexity, chemotherapy, specialized consultation, emergencies, oncological surgery, and radiotherapy or nuclear medicine. The information is reported in absolute frequencies. RESULTS: Seventy one institutions have hematology-oncology consultation, 39 institutions have chemotherapy and hospitalization services of medium or high complexity, and 18 have radiotherapy enabled. Only nine of the institutions include all the services that are necessary for comprehensive care. CONCLUSION: Colombia has a sufficient supply of services for the care of children with cancer. Only a minority are in institutions that have the capacity to guarantee the integrality of the attention.

ANTECEDENTES: En los países de bajos ingresos un niño diagnosticado con cáncer tiene un 80% de probabilidad de morir mientras que en los países de ingresos altos más del 80% sobrevive a la enfermedad. En Colombia, un país de ingresos medios, el gobierno expidió una nueva legislación que promueve la generación de unidades de atención integral; sin embargo, siete años después de su expedición, ninguna Institución ha sido reconocida como tal por el Ministerio de Salud. OBJETIVO: Caracterizar la actual oferta de servicios oncológicos para atención de cáncer en niños e identificar las instituciones que podrían ser constituirse en Unidades de Atención Integral de Cáncer Infantil en Colombia. MÉTODOS: estudio descriptivo de fuente secundaria, se consultó el Registro Especial de Prestadores de Salud del Ministerio de Salud y Protección Social; identificando las instituciones que tenían habilitados servicio de hospitalización de mediana o alta complejidad, quimioterapia, consulta especializada, urgencias, cirugía oncológica, radioterapia o medicina nuclear. Se reporta la información en frecuencias absolutas. RESULTADOS: Setenta y una instituciones cuentan con consulta de hemato-Oncología, 39 instituciones tienen servicios de quimioterapia y hospitalización de mediana o alta complejidad y 18 tienen habilitada radioterapia. Solo nueve de las instituciones incluyen la totalidad de los servicios necesarios para la atención integral. CONCLUSIÓN: Colombia cuenta con una oferta suficiente de servicios para atención de niños con cáncer. Solo una minoría se encuentra en Instituciones que tienen la capacidad de garantizar la integralidad de la atención.

Detection and Genotyping of HPV DNA in a Group of Unvaccinated Young Women from Colombia: Baseline Measures Prior to Future Monitoring Program.

In 2012, Colombia launched human papillomavirus (HPV) vaccination program for girls ages 9 to 12, and in 2013, the target age was expanded to 9 to 17 years. Monitoring the changes of HPV infection prevalence among young women has been proposed as an endpoint for early assessment of HPV vaccination programs. However, the data on HPV prevalence in young ages are very limited. The purpose of this study was to determine the prevalence of HPV infection and the distribution of genotypes in a group of nonvaccinated women ages 18 to 25 years old in three Colombian cities as baseline for the monitoring of the HPV national vaccination program. A total of 1,782 sexually active women were included. Cervical smear samples were collected to perform the Pap smear and HPV DNA detection using a Linear Array HPV assay. Of the 1,782 specimens analyzed, 60.3% were positive for any HPV type; 42.2% were positive for high-risk HPV (HR-HVP) types, and 44.4% for low-risk HPV (LR-HPV) types. Multiple and single infections were identified in 37.1% and 23.2% of samples, respectively. HR-HPV types -16, -52, and -51 were the most predominant with proportions of 11.3%, 7.92%, and 7.9%, correspondingly. The prevalence for HR-HPV 16/18 was 14.4%. HR-HPV prevalence in women with abnormal cytology (75.16%) was higher than in women with normal cytology (38.6%). In conclusion, a high prevalence of HR-HPV was observed among younger women. This HPV type-specific prevalence baseline may be used to monitor postvaccination longitudinal changes and to determine its impact on HPV-related disease incidence in Colombia population. Cancer Prev Res; 11(9); 581-92. ©2018 AACR.

Impact of operational factors on HPV positivity rates in an HPV-based screening study in Colombia.

OBJECTIVE: To assess the effect of operational factors on the positivity rates of three HPV assays. METHODS: Within the cross-sectional ESTAMPA study, women aged 30-64 years were recruited at healthcare centers from Soacha, Colombia, during 2012-2015. Cervical samples were collected for cotesting with Hybrid Capture 2 (HC2; Qiagen, Gaithersburg, MD, USA), and either Aptima (Hologic, Marlborough, MA, USA) or Cobas 4800 (Roche Diagnostics, Indianapolis, IN, USA). The effect of operational factors on assay performance was assessed using adjusted positivity rates obtained from logistic regression models. RESULTS: There were 4168 women included. For samples collected in assay-specific medium, positivity rate differences were associated with the expertise of the nurse collecting the sample (P=0.014 HC2; P=0.091 Aptima) and if sample collection occurred after an initial cytology (P=0.025 HC2; P=0.033 Aptima). If PreservCyt medium (Hologic) was used, HC2 positivity differences were observed depending on the time between sample collection and processing (P=0.026) and on the laboratory technician processing the samples (P=0.003). No differences were observed for PreservCyt samples processed with Aptima or Cobas. CONCLUSION: Nurse expertise, collection of previous cytology, processing time, and laboratory technician could influence HPV assay performance. Suitable quality assurance protocols for HPV-based screening programs are required. ClinicalTrials.gov: NCT01881659.

Oncology services supply in Colombia / Servicios oncológicos en Colombia

Abstract Objective: To characterize the current status of oncological services supply in Colombia. Methods: A descriptive analysis of oncological services for cancer care in the adult and infant population that meet the requirements for operation according to the Special Register of Health Service Providers was carried out. The case - by - provider ratio was calculated based on the cancer incidence estimated for Colombia by the National Cancer Institute. Results: Were identified 1,780 qualified oncology health services in the country related to specialties for providing care to cancer patients. Twenty five providers nationwide had all three qualified services: chemotherapy, radiotherapy and surgery. Nearly 50% of the offer was concentrated in Bogotá, Antioquia and Valle del Cauca. Putumayo and the Amazonas group departments, with the exception of Vaupés, did not show any oncological services. Healthcare Providers were responsible for 87.8%, and independent professionals provided 12.2%. Outpatient services were 66.7% of oncology services, 17.4% was diagnostic support services and therapeutic complementation, and 15.9% was surgical services. 87.9% of the oncological service offer in Colombia takes place in the private sector. Conclusions: The ratio between the service groups is asymmetric, with few providers jointly offering the basic services for oncology treatment, which reflects how provision is fragmented. It is necessary to redefine the concept of oncology service under a comprehensive care approach and the importance of enabling functional units, comprehensive treatment centers and other forms of care.

Resumen Objetivo: Caracterizar la situación actual de la oferta de servicios oncológicos en Colombia. Métodos: Se realizó un análisis descriptivo de los servicios oncológicos para la atención de cáncer en población adulta e infantil, que cumplieron con los requisitos para su funcionamiento de acuerdo al Registro Especial de Prestadores de Servicios de Salud. La razón de casos por prestador se calculó a partir de la incidencia de cáncer estimada para Colombia por el Instituto Nacional de Cancerología. Resultados: Se identificaron 1,780 servicios de salud oncológicos habilitados en el país relacionados con especialidades para la atención de pacientes con cáncer. 25 prestadores a nivel nacional contaron con los tres servicios habilitados: quimioterapia, radioterapia y cirugía. Cerca del 50% de la oferta se concentró en Bogotá, Antioquia y Valle del Cauca. Los departamentos de Putumayo y del grupo Amazonas, con excepción de Vaupés, no registraron servicios oncológicos. El 87.8% fue ofertado por Instituciones Prestadoras de Salud y el 12.2% fue provisto por profesionales independientes. El 66.7% de los servicios oncológicos eran de consulta externa, el 17.4% eran servicios de apoyo diagnóstico y complementación terapéutica y el 15.9% servicios quirúrgicos. El 87.9% de la oferta de servicios oncológicos en Colombia está en el sector privado. Conclusiones: La relación entre los grupos de servicios es asimétrica, con pocos prestadores que ofertan de forma conjunta los servicios bases del tratamiento oncológico, lo cual refleja la fragmentación en la prestación. Es necesario redefinir el concepto de servicio oncológico bajo el enfoque de atención integral y la importancia de habilitar unidades funcionales, centros integrales de tratamiento y otras formas de atención.